Pharma Leader Series: Top 20 Biological Drug Manufacturers 2012-2022
New study shows you commercial prospects for leading biopharmaceutical companies
How are companies in the biological medicines (biologics) industry performing? Visiongain's new report shows you organisations' prospects to 2022. There you find financial data, trends, opportunities and commercial potentials.
We assess 20 leading developers and producers of biological drugs and vaccines - our analyses help you see the future of the biopharma industry and market. See how sales can increase.
In our investigation you discover a biologics revenue forecast for each company, growth rates, rankings and market shares. Also, you see qualitative analyses, news, research and development (R&D) and business outlooks. You receive 113 tables and 80 charts.
Our work lets you assess the most lucrative areas of the biologicals market, especially 20 companies at the forefront of biopharmaceuticals. Their technologies hold great promise.
You can stay ahead in knowledge. The following sections highlight what you find in the report.
The leading company - you find prospects to 2022 for Roche
Roche is the first company our study analyses. See information on its products and activities in 2012, looking ahead.
You find discussions and analysis of its product portfolio:
You see prospects for leading pharmaceutical biotechs and specialist manufacturers
Our report gives you profiles and analyses for many other companies, including biopharmaceutical specialists such as these:
You discover prospects for other leading developers and manufacturers of biological drugs
Our investigation shows you prospects for other biological medicine producers, including revenue forecasts to 2022 with discussions.
See prospects for other leading European companies:
You investigate what affects companies and their market, seeing its revenue prospects too
Our report also analyses and discusses the overall market for biological drugs and vaccines. You see what influences the biopharma sector from 2012:
You also assess biological therapies by overall world market and product class (five submarkets), seeing forecasted revenues, sales shares and growth rates to 2022.
The biologics segment is growing faster than the overall world pharmaceutical market, a trend that will continue, our analyses predict. From 2012, biologic blockbusters will fill many of the top sales places. Also, most of those products will continue revenue growth.
Seven ways Pharma Leader Series: Top 20 Biological Drug Manufacturers 2012-2022 helps you
In particular, our report gives you the following knowledge on producers of biologics:
There you find business intelligence to help you understand the future of the biologicals industry and market. You see where prospects are lucrative, where growth is likely.
With our report you are less likely to fall behind in knowledge. Discover how our work could benefit your research and analyses, saving you time too.
You see prospects for biologics manufacturers by ordering now
Visiongain's study is for everybody needing commercial analysis of healthcare biotechnology. You find data, trends and predictions. Please order our report now.
Visiongain is a trading partner with the US Federal Government
How are companies in the biological medicines (biologics) industry performing? Visiongain's new report shows you organisations' prospects to 2022. There you find financial data, trends, opportunities and commercial potentials.
We assess 20 leading developers and producers of biological drugs and vaccines - our analyses help you see the future of the biopharma industry and market. See how sales can increase.
In our investigation you discover a biologics revenue forecast for each company, growth rates, rankings and market shares. Also, you see qualitative analyses, news, research and development (R&D) and business outlooks. You receive 113 tables and 80 charts.
Our work lets you assess the most lucrative areas of the biologicals market, especially 20 companies at the forefront of biopharmaceuticals. Their technologies hold great promise.
You can stay ahead in knowledge. The following sections highlight what you find in the report.
The leading company - you find prospects to 2022 for Roche
Roche is the first company our study analyses. See information on its products and activities in 2012, looking ahead.
You find discussions and analysis of its product portfolio:
- Rituxan
- Avastin
- Herceptin
- Lucentis
- Pegasys and other agents.
You see prospects for leading pharmaceutical biotechs and specialist manufacturers
Our report gives you profiles and analyses for many other companies, including biopharmaceutical specialists such as these:
- Sanofi
- Novo Nordisk
- Pfizer
- GlaxoSmithKline (GSK)
- Merck & Co.
- Novartis
- Amgen
- Biogen Idec
- CSL Behring
- Grifols
- Allergan.
You discover prospects for other leading developers and manufacturers of biological drugs
Our investigation shows you prospects for other biological medicine producers, including revenue forecasts to 2022 with discussions.
See prospects for other leading European companies:
- Merck KGaA
- Bayer
- AstraZeneca.
- Johnson & Johnson (J&J)
- Abbott Laboratories
- Baxter
- Eli Lilly
- Bristol-Myers Squibb (BMS).
You investigate what affects companies and their market, seeing its revenue prospects too
Our report also analyses and discusses the overall market for biological drugs and vaccines. You see what influences the biopharma sector from 2012:
- Competition, collaborations, technology and product licensing
- Corporations, mergers and acquisitions (M&A deals - e.g. GSK and Human Genome Sciences in summer 2012)
- R&D - immunotherapies, plasma agents, hormones and other proteins and recombinant molecules, including cellular therapies
- Opportunities in treating cancers, CNS disorders, inflammatory diseases, viral infections, blood ailments, diabetes, eye diseases and other medical conditions
- Strengths, weaknesses, opportunities and threats, including the entry of biosimilars and follow-on protein products.
You also assess biological therapies by overall world market and product class (five submarkets), seeing forecasted revenues, sales shares and growth rates to 2022.
The biologics segment is growing faster than the overall world pharmaceutical market, a trend that will continue, our analyses predict. From 2012, biologic blockbusters will fill many of the top sales places. Also, most of those products will continue revenue growth.
Seven ways Pharma Leader Series: Top 20 Biological Drug Manufacturers 2012-2022 helps you
In particular, our report gives you the following knowledge on producers of biologics:
- Profiles of 20 leading companies - discover products, recent results, sales breakdowns, strategies, competition and outlooks
- Forecasted revenues to 2022 for the 20 leading companies - analyse predicted financial results for each company
- Potential revenues to 2022 for the overall world market and 5 biological product submarkets - find the biopharma industry's sales prospects
- Review of R&D pipelines - investigate developmental trends and progress
- Investigation of competition and opportunities influencing biomedical sales
- Discussion of what stimulates and restrains companies, the industry and the market
- Prospects for established businesses and firms entering biopharma.
There you find business intelligence to help you understand the future of the biologicals industry and market. You see where prospects are lucrative, where growth is likely.
With our report you are less likely to fall behind in knowledge. Discover how our work could benefit your research and analyses, saving you time too.
You see prospects for biologics manufacturers by ordering now
Visiongain's study is for everybody needing commercial analysis of healthcare biotechnology. You find data, trends and predictions. Please order our report now.
Visiongain is a trading partner with the US Federal Government
1. EXECUTIVE SUMMARY
1.1 Leading Biological Drug Manufacturers: Overview of Findings
1.2 Chapter Breakdown
1.3 Research and Analysis Methods
1.4 Scope of this Report
1.4.1 Drugs Considered for this Report
2. OVERVIEW OF THE WORLD BIOLOGICALS MARKET, 2012-2022
2.1 Biological Drugs
2.1.1 Defining the Field
2.2 The Biological Drugs Market, 2011
2.3 Leading Classes of Biological Drug
2.3.1 Therapeutic Proteins
2.3.2 Monoclonal Antibodies (MAbs)
2.3.3 Vaccines
2.3.4 Fusion Proteins
2.3.5 Other Biological Drugs
2.4 The Biological Drugs Market: Overall Revenue Forecast, 2012-2022
2.5. The Biological Drugs Market: Drivers and Restraints, 2012
2.6 Leading 20 Biological Drug Manufacturers, 2011
3. THE LEADING BIOLOGICS MANUFACTURER: ROCHE, 2012-2022
3.1 Roche Biologics in 2012: Overview
3.2 Roche Biologics Portfolio, 2012
3.2.1 Rituxan (rituximab)
3.2.2 Avastin (bevacizumab)
3.2.3 Herceptin (trastuzumab)
3.2.4 Lucentis (ranibizumab)
3.2.5 Pegasys (pegylated interferon alpha 2a)
3.2.6 Other Roche Biologics
3.3 Roche Biologics Pipeline, 2012
3.3.1 Obinituzumab (RG7159, GA101)
3.3.2 Onartuzumab (MetMAb, RG3638)
3.3.3 Trastuzumab emtansine (T-DM1, RG3502)
3.3.4 Ocrelizumab (RG1594)
3.3.5 Lebrikizumab
3.3.6 Gantenerumab (RG1450)
3.4 Drivers and Restraints for Roche Biologics, 2012
3.5 Roche Biologics Revenue Forecast, 2012-2022
4. BIOTECHS AND SPECIALIST MANUFACTURERS, 2012-2022
4.1 Amgen, 2012
4.1.1 Amgen Biologics in 2012: Overview
4.1.2 Amgen Biologics Portfolio, 2012
4.1.2.1 Enbrel (etanercept)
4.1.2.2 Neulasta/Neupogen (pegfilgrastim/filgrastim)
4.1.2.3 Epogen (epoetin alpha)/ Aranesp (darbepoietin alpha)
4.1.2.4 Other Amgen Biologics
4.1.3 Amgen's Biologics Pipeline, 2012
4.1.3.1 AMG386
4.1.3.2 Ganitumab (AMG 479)
4.1.3.3 Talimogene Laherparepvec
4.1.3.4 AMG145
4.1.3.5 AMG785
4.1.4 Amgen Drivers and Restraints, 2012
4.1.5 Amgen Biologics Revenue Forecast, 2012-2022
4.2 Biogen Idec, 2012
4.2.1 Biogen Idec Biologics in 2012: Overview
4.2.2 Biogen Idec's Product Portfolio, 2012
4.2.2.1 Avonex (beta-interferon 1a)
4.2.2.2 Tysabri (natalizumab)
4.2.3 Biogen Idec's Biologics Pipeline, 2012
4.2.3.1 PEG-interferon beta-1a (BIIB 017)
4.2.3.2 Recombinant Factor VIII-Fc and Factor IX-Fc
4.2.3.3 Galiximab
4.2.4 Biogen Idec Drivers and Restraints, 2012
4.2.5 Biogen Idec Biologics Revenue Forecast, 2012-2022
4.3 CSL Behring, 2012
4.3.1 CSL Behring Biologics in 2012: Overview
4.3.2 CSL's Product Portfolio, 2012
4.3.2.1 Immunoglobulins
4.3.2.2 Plasma-Derived Coagulants
4.3.2.3 Helixate
4.3.2.4 Albumin
4.3.3 CSL's Biologics Pipeline, 2012
4.3.3.1 Overview of New Products
4.3.4 Drivers and Restraints for CSL
4.3.5 CSL Biologics Revenue Forecast, 2012-2022
4.4 Grifols, 2012
4.4.1 Grifols Biologics in 2012: Overview
4.4.2 Grifols' Product Portfolio, 2012
4.4.2.1 Gamunex/Gamunex-C (Immune Globulin Injection, 10% Caprylate/Chromatography Purified)
4.4.2.2 Prolastin/ Prolastin-C (Alpha-1 Proteinase Inhibitor)
4.4.2.3 Fraction VIII (Koate DVI)
4.4.3 Grifols' Biologics Pipeline, 2012
4.4.3.1 Plasma-Derived and Recombinant Plasmins
4.4.4 Drivers and Restraints for Grifols Biologics, 2012
4.4.5 Market Forecast for Grifols Biologics, 2012-2022
4.5 Allergan, 2012
4.5.1 Allergan Biologics: Overview, 2012
4.5.2 Allergan Product Portfolio, 2012
4.5.3 Allergan Biologics Pipeline: Overview, 2012
4.5.4 Drivers and Restraints for Allergan Biologics, 2012
4.5.5 Market Forecast for Allergan Biologics, 2012-2022
5. LEADING VACCINES MANUFACTURERS, 2012-2022
5.1 Sanofi, 2012
5.1.1 Sanofi Biologics: Overview, 2012
5.1.2 Sanofi Biologics Portfolio, 2012
5.1.2.1 Lantus (insulin glargine)
5.1.2.2 Genzyme Legacy Products
5.1.2.3 Polio/Pertussis/Hib Vaccines
5.1.2.4 Influenza Vaccines
5.1.2.5 Other Sanofi Biologics
5.1.3 Sanofi Biologics Pipeline, 2012
5.1.3.1 Hexaxim (DTP-HepB-Polio-Hib Vaccine)
5.1.3.2 Dengue Fever Vaccine
5.1.3.3 Zaltrap (aflibercept)
5.1.3.4 Sarilumab
5.1.4 Drivers and Restraints for Sanofi Biologics, 2012
5.1.5 Market Forecast for Sanofi Biologics, 2012-2022
5.2 Pfizer, 2012
5.2.1 Pfizer Biologics: Overview, 2012
5.2.2 Pfizer Biologics Portfolio, 2012
5.2.2.1 Prevnar-13/Prevnar-7 (Pneumococcal 13-Valent/ 7-Valent Conjugate Vaccine)
5.2.3 Pfizer Biologics Pipeline, 2012
5.2.3.1 Inotuzumab Ozogamicin
5.2.3.2 Fezakinumab
5.2.3.3 Ozoralizumab
5.2.3.4 Tanezumab (RN624)
5.2.4 Drivers and Restraints for Pfizer Biologics
5.2.5 Market Forecast for Pfizer Biologics, 2012-2022
5.3 GlaxoSmithKline, 2012
5.3.1 GlaxoSmithKline Biologics: Overview, 2012
5.3.2 GlaxoSmithKline Biologics Portfolio, 2012
5.3.2.1 Infanrix/Pediarix
5.3.2.2 Hepatitis Vaccines
5.3.2.3 Cervarix
5.3.2.4 Synflorix
5.3.2.5 Other GlaxoSmithKline Biologics, 2012
5.3.3 GlaxoSmithKline Biologics Pipeline, 2012
5.3.3.1 Astuprotimut (MAGE-A3 Therapeutic Vaccine)
5.3.3.2 Menhibrix (Meningitis C and Y and Hib Vaccine)
5.3.3.3 GSK1437173A (Varicella Zoster Virus Vaccine)
5.3.3.4 Mosquirix
5.3.3.5 Nimenrix
5.3.4 Drivers and Restraints for GlaxoSmithKline Biologics, 2012
5.3.5 Market Forecast for GlaxoSmithKline, 2012-2022
5.4 Merck & Co., 2012
5.4.1 Merck Biologics: Overview, 2012
5.4.2 Merck Biologics Portfolio: Overview, 2012
5.4.2.1 Gardasil
5.4.2.2 ProQuad/ MMR-II/ Varivax
5.4.2.3 PegIntron (peginterferon alpha-2b)
5.4.2.4 RotaTeq
5.4.2.5 Other Merck Biologics, 2012
5.4.3 Merck Biologics Pipeline, 2012
5.4.3.1 V503
5.4.3.2 V212
5.4.3.3 Allergy Vaccines
5.4.3.4 MK-0646
5.4.4 Drivers and Restraints for Merck Biologics, 2012
5.4.5 Market Forecast for Merck Biologics, 2012-2022
5.5 Novartis, 2012
5.5.1 Novartis Biologics: Overview, 2012
5.5.2 Novartis Biologics Portfolio, 2012
5.5.2.1 Novartis Vaccines
5.5.3 Novartis Biologics Pipeline, 2012
5.5.3.1 Bexsero
5.5.4 Drivers and Restraints for Novartis Biologics, 2012
5.5.5 Market Forecast for Novartis Biologics, 2012-2022
6. LEADING EUROPEAN BIOLOGICS MANUFACTURERS, 2012-2022
6.1 Novo Nordisk, 2012
6.1.1 Novo Nordisk Biologics: Overview, 2012
6.1.2 Novo Nordisk's Biologics Portfolio, 2012
6.1.2.1 NovoRapid/ NovoLog (insulin aspart)
6.1.2.2 NovoSeven (eptacog alpha)
6.1.2.3 Levemir (insulin detemir)
6.1.2.4 Norditropin (Somatropin Injection)
6.1.3 Novo Nordisk's Biologics Pipeline, 2012
6.1.3.1 Tresiba (Insulin Degludec)
6.1.3.2 Catridecacog
6.1.3.3 NN7008
6.1.4 Drivers and Restraints for Novo Nordisk
6.1.5 Market Forecast for Novo Nordisk Biologics, 2012-2022
6.2 Merck KGaA
6.2.1 Merck KGaA Biologics: Overview
6.2.2 Merck KGaA Portfolio, 2012
6.2.2.1 Rebif (interferon beta-1a)
6.2.2.2 Erbitux (cetuximab)
6.2.3 Merck KGaA Pipeline, 2012
6.2.3.1 Atacicept (TACI-Ig)
6.2.3.2 Adecatumumab
6.2.3.3 Stimuvax (emepepimut-S)
6.2.3.4 SEED Bodies
6.2.4 Drivers and Restraints for Merck KGaA
6.2.5. Market Forecast for Merck KGaA
6.3 Bayer
6.3.1 Bayer Biologics: Overview, 2012
6.3.2 Bayer Biologics Portfolio, 2012
6.3.2.1 Betaferon (interferon beta-1b)
6.3.2.2 Kogenate (recombinant Factor VIII)
6.3.2.3 Eylea (aflibercept)
6.3.3 Bayer Pipeline, 2012
6.3.3.1 L19-131I
6.3.3.2 L19-TNF
6.3.3.3 BAY 94-9027
6.3.4 Drivers and Restraints for Bayer Biologics, 2012
6.3.5 Market Forecast for Bayer Biologics, 2012-2022
6.4 AstraZeneca
6.4.1 AstraZeneca Biologics Overview, 2012
6.4.2 AstraZeneca Biologics Portfolio, 2012
6.4.2.1 Synagis (palivizumab)
6.4.3 AstraZeneca Biologics Pipeline, 2012
6.4.4 AstraZeneca Biologics Drivers and Restraints, 2012
6.4.5 AstraZeneca Market Forecast, 2012-2022
7. LEADING US BIOLOGICS MANUFACTURERS, 2012-2022
7.1 Johnson & Johnson
7.1.1 Johnson & Johnson Biologics: Overview, 2012
7.1.2 Johnson & Johnson Biologics Portfolio
7.1.2.1 Remicade (infliximab)
7.1.2.2 Stelara (ustekinumab)
7.1.2.3 Other Johnson & Johnson Biologics
7.1.3 Johnson & Johnson Biologics Pipeline
7.1.3.1 Bapineuzumab
7.1.3.2 Fulranumab
7.1.3.3 CNTO 328 (siltuximab)
7.1.4 Johnson & Johnson Biologics Drivers and Restraints, 2012
7.1.5 Johnson & Johnson Market Forecast, 2012-2022
7.2 Abbott Laboratories
7.2.1 Abbott Laboratories Biologics: Overview, 2012
7.2.2 Abbott Laboratories Biologics Portfolio, 2012
7.2.2.1 Humira (adalimumab)
7.2.3 Abbott Laboratories Biologics Pipeline, 2012
7.2.3.1 Daclizumab
7.2.4 Abbott Laboratories Biologics Drivers and Restraints, 2012
7.2.5 Abbott Laboratories Biologics Market Forecast, 2012-2022
7.3 Baxter
7.3.1 Baxter Biologics: Overview, 2012
7.3.2 Baxter Biologics Portfolio, 2012
7.3.2.1 Recombinants
7.3.2.2 Other Areas
7.3.3 Baxter Biologics Pipeline, 2012
7.3.3.1 BAX111 (Recombinant von Willebrand Factor)
7.3.3.2 Adult Autologous Stem Cell Therapy
7.3.3.3 KUR-211 (Growth Factor)
7.3.4 Baxter Biologics Drivers and Restraints, 2012
7.3.5 Baxter Biologics Market Forecast, 2012-2022
7.4 Eli Lilly, 2012
7.4.1 Eli Lilly Biologics: Overview, 2012
7.4.2 Eli Lilly Biologics Portfolio, 2012
7.4.2.1 Humalog(insulin lispro)
7.4.2.2 Humulin
7.4.3 Eli Lilly Biologics Pipeline, 2012
7.4.3.1 Liprotamase (Enzyme Replacement Therapy)
7.4.3.2 Solanezumab
7.4.3.3 Necitumumab
7.4.3.4 Ramicirumab
7.4.3.5 GLP1 FC Fusion Protein
7.4.3.6 Tabalumab
7.4.4 Eli Lilly Biologics Drivers and Restraints, 2012
7.4.5 Eli Lilly Biologics Market Forecast, 2012-2022
7.5 Bristol-Myers Squibb, 2012
7.5.1 Bristol-Myers Squibb Biologics: Overview, 2012
7.5.2 Bristol-Myers Squibb Biologics Portfolio, 2012
7.5.2.1 Orencia (abatacept)
7.5.2.2 Other Bristol-Myers Squibb Biologics
7.5.3 Bristol-Myers Squibb Biologics Pipeline, 2012
7.5.3.1 Elotuzumab
7.5.3.2 Anti-PD1 MAb (BMS-936558)
7.5.4 Bristol-Myers Squibb Biologics Drivers and Restraints, 2012
7.5.5 Bristol-Myers Squibb Biologics Market Forecast, 2012-2022
1.1 Leading Biological Drug Manufacturers: Overview of Findings
1.2 Chapter Breakdown
1.3 Research and Analysis Methods
1.4 Scope of this Report
1.4.1 Drugs Considered for this Report
2. OVERVIEW OF THE WORLD BIOLOGICALS MARKET, 2012-2022
2.1 Biological Drugs
2.1.1 Defining the Field
2.2 The Biological Drugs Market, 2011
2.3 Leading Classes of Biological Drug
2.3.1 Therapeutic Proteins
2.3.2 Monoclonal Antibodies (MAbs)
2.3.3 Vaccines
2.3.4 Fusion Proteins
2.3.5 Other Biological Drugs
2.4 The Biological Drugs Market: Overall Revenue Forecast, 2012-2022
2.5. The Biological Drugs Market: Drivers and Restraints, 2012
2.6 Leading 20 Biological Drug Manufacturers, 2011
3. THE LEADING BIOLOGICS MANUFACTURER: ROCHE, 2012-2022
3.1 Roche Biologics in 2012: Overview
3.2 Roche Biologics Portfolio, 2012
3.2.1 Rituxan (rituximab)
3.2.2 Avastin (bevacizumab)
3.2.3 Herceptin (trastuzumab)
3.2.4 Lucentis (ranibizumab)
3.2.5 Pegasys (pegylated interferon alpha 2a)
3.2.6 Other Roche Biologics
3.3 Roche Biologics Pipeline, 2012
3.3.1 Obinituzumab (RG7159, GA101)
3.3.2 Onartuzumab (MetMAb, RG3638)
3.3.3 Trastuzumab emtansine (T-DM1, RG3502)
3.3.4 Ocrelizumab (RG1594)
3.3.5 Lebrikizumab
3.3.6 Gantenerumab (RG1450)
3.4 Drivers and Restraints for Roche Biologics, 2012
3.5 Roche Biologics Revenue Forecast, 2012-2022
4. BIOTECHS AND SPECIALIST MANUFACTURERS, 2012-2022
4.1 Amgen, 2012
4.1.1 Amgen Biologics in 2012: Overview
4.1.2 Amgen Biologics Portfolio, 2012
4.1.2.1 Enbrel (etanercept)
4.1.2.2 Neulasta/Neupogen (pegfilgrastim/filgrastim)
4.1.2.3 Epogen (epoetin alpha)/ Aranesp (darbepoietin alpha)
4.1.2.4 Other Amgen Biologics
4.1.3 Amgen's Biologics Pipeline, 2012
4.1.3.1 AMG386
4.1.3.2 Ganitumab (AMG 479)
4.1.3.3 Talimogene Laherparepvec
4.1.3.4 AMG145
4.1.3.5 AMG785
4.1.4 Amgen Drivers and Restraints, 2012
4.1.5 Amgen Biologics Revenue Forecast, 2012-2022
4.2 Biogen Idec, 2012
4.2.1 Biogen Idec Biologics in 2012: Overview
4.2.2 Biogen Idec's Product Portfolio, 2012
4.2.2.1 Avonex (beta-interferon 1a)
4.2.2.2 Tysabri (natalizumab)
4.2.3 Biogen Idec's Biologics Pipeline, 2012
4.2.3.1 PEG-interferon beta-1a (BIIB 017)
4.2.3.2 Recombinant Factor VIII-Fc and Factor IX-Fc
4.2.3.3 Galiximab
4.2.4 Biogen Idec Drivers and Restraints, 2012
4.2.5 Biogen Idec Biologics Revenue Forecast, 2012-2022
4.3 CSL Behring, 2012
4.3.1 CSL Behring Biologics in 2012: Overview
4.3.2 CSL's Product Portfolio, 2012
4.3.2.1 Immunoglobulins
4.3.2.2 Plasma-Derived Coagulants
4.3.2.3 Helixate
4.3.2.4 Albumin
4.3.3 CSL's Biologics Pipeline, 2012
4.3.3.1 Overview of New Products
4.3.4 Drivers and Restraints for CSL
4.3.5 CSL Biologics Revenue Forecast, 2012-2022
4.4 Grifols, 2012
4.4.1 Grifols Biologics in 2012: Overview
4.4.2 Grifols' Product Portfolio, 2012
4.4.2.1 Gamunex/Gamunex-C (Immune Globulin Injection, 10% Caprylate/Chromatography Purified)
4.4.2.2 Prolastin/ Prolastin-C (Alpha-1 Proteinase Inhibitor)
4.4.2.3 Fraction VIII (Koate DVI)
4.4.3 Grifols' Biologics Pipeline, 2012
4.4.3.1 Plasma-Derived and Recombinant Plasmins
4.4.4 Drivers and Restraints for Grifols Biologics, 2012
4.4.5 Market Forecast for Grifols Biologics, 2012-2022
4.5 Allergan, 2012
4.5.1 Allergan Biologics: Overview, 2012
4.5.2 Allergan Product Portfolio, 2012
4.5.3 Allergan Biologics Pipeline: Overview, 2012
4.5.4 Drivers and Restraints for Allergan Biologics, 2012
4.5.5 Market Forecast for Allergan Biologics, 2012-2022
5. LEADING VACCINES MANUFACTURERS, 2012-2022
5.1 Sanofi, 2012
5.1.1 Sanofi Biologics: Overview, 2012
5.1.2 Sanofi Biologics Portfolio, 2012
5.1.2.1 Lantus (insulin glargine)
5.1.2.2 Genzyme Legacy Products
5.1.2.3 Polio/Pertussis/Hib Vaccines
5.1.2.4 Influenza Vaccines
5.1.2.5 Other Sanofi Biologics
5.1.3 Sanofi Biologics Pipeline, 2012
5.1.3.1 Hexaxim (DTP-HepB-Polio-Hib Vaccine)
5.1.3.2 Dengue Fever Vaccine
5.1.3.3 Zaltrap (aflibercept)
5.1.3.4 Sarilumab
5.1.4 Drivers and Restraints for Sanofi Biologics, 2012
5.1.5 Market Forecast for Sanofi Biologics, 2012-2022
5.2 Pfizer, 2012
5.2.1 Pfizer Biologics: Overview, 2012
5.2.2 Pfizer Biologics Portfolio, 2012
5.2.2.1 Prevnar-13/Prevnar-7 (Pneumococcal 13-Valent/ 7-Valent Conjugate Vaccine)
5.2.3 Pfizer Biologics Pipeline, 2012
5.2.3.1 Inotuzumab Ozogamicin
5.2.3.2 Fezakinumab
5.2.3.3 Ozoralizumab
5.2.3.4 Tanezumab (RN624)
5.2.4 Drivers and Restraints for Pfizer Biologics
5.2.5 Market Forecast for Pfizer Biologics, 2012-2022
5.3 GlaxoSmithKline, 2012
5.3.1 GlaxoSmithKline Biologics: Overview, 2012
5.3.2 GlaxoSmithKline Biologics Portfolio, 2012
5.3.2.1 Infanrix/Pediarix
5.3.2.2 Hepatitis Vaccines
5.3.2.3 Cervarix
5.3.2.4 Synflorix
5.3.2.5 Other GlaxoSmithKline Biologics, 2012
5.3.3 GlaxoSmithKline Biologics Pipeline, 2012
5.3.3.1 Astuprotimut (MAGE-A3 Therapeutic Vaccine)
5.3.3.2 Menhibrix (Meningitis C and Y and Hib Vaccine)
5.3.3.3 GSK1437173A (Varicella Zoster Virus Vaccine)
5.3.3.4 Mosquirix
5.3.3.5 Nimenrix
5.3.4 Drivers and Restraints for GlaxoSmithKline Biologics, 2012
5.3.5 Market Forecast for GlaxoSmithKline, 2012-2022
5.4 Merck & Co., 2012
5.4.1 Merck Biologics: Overview, 2012
5.4.2 Merck Biologics Portfolio: Overview, 2012
5.4.2.1 Gardasil
5.4.2.2 ProQuad/ MMR-II/ Varivax
5.4.2.3 PegIntron (peginterferon alpha-2b)
5.4.2.4 RotaTeq
5.4.2.5 Other Merck Biologics, 2012
5.4.3 Merck Biologics Pipeline, 2012
5.4.3.1 V503
5.4.3.2 V212
5.4.3.3 Allergy Vaccines
5.4.3.4 MK-0646
5.4.4 Drivers and Restraints for Merck Biologics, 2012
5.4.5 Market Forecast for Merck Biologics, 2012-2022
5.5 Novartis, 2012
5.5.1 Novartis Biologics: Overview, 2012
5.5.2 Novartis Biologics Portfolio, 2012
5.5.2.1 Novartis Vaccines
5.5.3 Novartis Biologics Pipeline, 2012
5.5.3.1 Bexsero
5.5.4 Drivers and Restraints for Novartis Biologics, 2012
5.5.5 Market Forecast for Novartis Biologics, 2012-2022
6. LEADING EUROPEAN BIOLOGICS MANUFACTURERS, 2012-2022
6.1 Novo Nordisk, 2012
6.1.1 Novo Nordisk Biologics: Overview, 2012
6.1.2 Novo Nordisk's Biologics Portfolio, 2012
6.1.2.1 NovoRapid/ NovoLog (insulin aspart)
6.1.2.2 NovoSeven (eptacog alpha)
6.1.2.3 Levemir (insulin detemir)
6.1.2.4 Norditropin (Somatropin Injection)
6.1.3 Novo Nordisk's Biologics Pipeline, 2012
6.1.3.1 Tresiba (Insulin Degludec)
6.1.3.2 Catridecacog
6.1.3.3 NN7008
6.1.4 Drivers and Restraints for Novo Nordisk
6.1.5 Market Forecast for Novo Nordisk Biologics, 2012-2022
6.2 Merck KGaA
6.2.1 Merck KGaA Biologics: Overview
6.2.2 Merck KGaA Portfolio, 2012
6.2.2.1 Rebif (interferon beta-1a)
6.2.2.2 Erbitux (cetuximab)
6.2.3 Merck KGaA Pipeline, 2012
6.2.3.1 Atacicept (TACI-Ig)
6.2.3.2 Adecatumumab
6.2.3.3 Stimuvax (emepepimut-S)
6.2.3.4 SEED Bodies
6.2.4 Drivers and Restraints for Merck KGaA
6.2.5. Market Forecast for Merck KGaA
6.3 Bayer
6.3.1 Bayer Biologics: Overview, 2012
6.3.2 Bayer Biologics Portfolio, 2012
6.3.2.1 Betaferon (interferon beta-1b)
6.3.2.2 Kogenate (recombinant Factor VIII)
6.3.2.3 Eylea (aflibercept)
6.3.3 Bayer Pipeline, 2012
6.3.3.1 L19-131I
6.3.3.2 L19-TNF
6.3.3.3 BAY 94-9027
6.3.4 Drivers and Restraints for Bayer Biologics, 2012
6.3.5 Market Forecast for Bayer Biologics, 2012-2022
6.4 AstraZeneca
6.4.1 AstraZeneca Biologics Overview, 2012
6.4.2 AstraZeneca Biologics Portfolio, 2012
6.4.2.1 Synagis (palivizumab)
6.4.3 AstraZeneca Biologics Pipeline, 2012
6.4.4 AstraZeneca Biologics Drivers and Restraints, 2012
6.4.5 AstraZeneca Market Forecast, 2012-2022
7. LEADING US BIOLOGICS MANUFACTURERS, 2012-2022
7.1 Johnson & Johnson
7.1.1 Johnson & Johnson Biologics: Overview, 2012
7.1.2 Johnson & Johnson Biologics Portfolio
7.1.2.1 Remicade (infliximab)
7.1.2.2 Stelara (ustekinumab)
7.1.2.3 Other Johnson & Johnson Biologics
7.1.3 Johnson & Johnson Biologics Pipeline
7.1.3.1 Bapineuzumab
7.1.3.2 Fulranumab
7.1.3.3 CNTO 328 (siltuximab)
7.1.4 Johnson & Johnson Biologics Drivers and Restraints, 2012
7.1.5 Johnson & Johnson Market Forecast, 2012-2022
7.2 Abbott Laboratories
7.2.1 Abbott Laboratories Biologics: Overview, 2012
7.2.2 Abbott Laboratories Biologics Portfolio, 2012
7.2.2.1 Humira (adalimumab)
7.2.3 Abbott Laboratories Biologics Pipeline, 2012
7.2.3.1 Daclizumab
7.2.4 Abbott Laboratories Biologics Drivers and Restraints, 2012
7.2.5 Abbott Laboratories Biologics Market Forecast, 2012-2022
7.3 Baxter
7.3.1 Baxter Biologics: Overview, 2012
7.3.2 Baxter Biologics Portfolio, 2012
7.3.2.1 Recombinants
7.3.2.2 Other Areas
7.3.3 Baxter Biologics Pipeline, 2012
7.3.3.1 BAX111 (Recombinant von Willebrand Factor)
7.3.3.2 Adult Autologous Stem Cell Therapy
7.3.3.3 KUR-211 (Growth Factor)
7.3.4 Baxter Biologics Drivers and Restraints, 2012
7.3.5 Baxter Biologics Market Forecast, 2012-2022
7.4 Eli Lilly, 2012
7.4.1 Eli Lilly Biologics: Overview, 2012
7.4.2 Eli Lilly Biologics Portfolio, 2012
7.4.2.1 Humalog(insulin lispro)
7.4.2.2 Humulin
7.4.3 Eli Lilly Biologics Pipeline, 2012
7.4.3.1 Liprotamase (Enzyme Replacement Therapy)
7.4.3.2 Solanezumab
7.4.3.3 Necitumumab
7.4.3.4 Ramicirumab
7.4.3.5 GLP1 FC Fusion Protein
7.4.3.6 Tabalumab
7.4.4 Eli Lilly Biologics Drivers and Restraints, 2012
7.4.5 Eli Lilly Biologics Market Forecast, 2012-2022
7.5 Bristol-Myers Squibb, 2012
7.5.1 Bristol-Myers Squibb Biologics: Overview, 2012
7.5.2 Bristol-Myers Squibb Biologics Portfolio, 2012
7.5.2.1 Orencia (abatacept)
7.5.2.2 Other Bristol-Myers Squibb Biologics
7.5.3 Bristol-Myers Squibb Biologics Pipeline, 2012
7.5.3.1 Elotuzumab
7.5.3.2 Anti-PD1 MAb (BMS-936558)
7.5.4 Bristol-Myers Squibb Biologics Drivers and Restraints, 2012
7.5.5 Bristol-Myers Squibb Biologics Market Forecast, 2012-2022
LIST OF TABLES
Table 1.1 Currency Exchange Rates, 2011
Table 2.2 Biological Drugs Market by Class, Revenues ($bn), Market Share (%), 2011
Table 2.3 Therapeutic Proteins: Role in the Biological Drugs Market, 2011
Table 2.4 MAbs: Role in the Biological Drugs Market, 2011
Table 2.5 Vaccines: Role in the Biological Drugs Market, 2011
Table 2.6 Fusion Proteins: Role in the Biological Drugs Market, 2011
Table 2.7 Other Biologics: Role in the Biological Drugs Market, 2011
Table 2.8 Biological Drugs Market by Class: Revenues ($bn), Market Share (%), CAGR (%), 2011, 2016, 2022
Table 2.9 Top 20 Biological Manufacturers: Revenue ($bn), Market Share (%), 2011
Table 3.1 Roche: Key Facts, 2012
Table 3.2 Roche: Leading Biologics, Revenues ($bn), Share of Biologics Revenue (%), 2011
Table 3.3 Roche: Selected Pipeline Biologics, Phase II and III, 2012
Table 3.4 Roche: Selected Pipeline Biologics, Phase I, 2012
Table 3.5 Roche Biologics, Market Forecast ($bn, AGR %, CAGR %), 2011-2016
Table 3.6 Roche Biologics, Market Forecast ($bn, AGR %, CAGR %), 2017-2022
Table 4.1 Amgen: Key Facts, 2012
Table 4.2 Amgen: Key M&A Deals, 2012
Table 4.3 Amgen: Lead Biologics Revenues ($bn), Share of Biologics Revenue (%), 2011
Table 4.4 Amgen: Selected Pipeline Biologics, 2012
Table 4.5 Amgen: Market Forecast ($bn, AGR %, CAGR %), 2011-2016
Table 4.6 Amgen: Market Forecast ($bn, AGR %, CAGR %), 2017-2022
Table 4.7 Biogen Idec: Key Facts, 2012
Table 4.8 Biogen Idec: Ongoing Collaborations, 2012
Table 4.9 Biogen Idec: Lead Biologics Revenues ($bn), Share of Biologics Revenue (%), 2011
Table 4.10 Biogen Idec: Selected Pipeline Biologics, 2012
Table 4.11 Biogen Idec: Market Forecast ($bn, AGR %, CAGR %), 2011-2016
Table 4.12 Biogen Idec: Market Forecast ($bn, AGR %, CAGR %), 2017-2022
Table 4.13 CSL Behring: Key Facts, 2012
Table 4.14 CSL: Shares of Company's Biologics Revenue (%), 2011
Table 4.15 CSL: Selected Pipeline Biologics, 2012
Table 4.16 CSL: Market Forecast ($bn, AGR %, CAGR %), 2011-2016
Table 4.17 CSL: Market Forecast ($bn, AGR %, CAGR %), 2017-2022
Table 4.18 Grifols: Key Facts, 2012
Table 4.19 Grifols: Selected Biologics, Revenues ($bn), 2010
Table 4.20 Grifols: Market Forecast ($bn, AGR %, CAGR %), 2011-2016
Table 4.21 Grifols: Market Forecast ($bn, AGR %, CAGR %), 2017-2022
Table 4.22 Allergan: Key Facts, 2012
Table 4.23 FDA-Approved On-Label Uses of Botox with Approval Date, 2012
Table 4.24 Allergan: Market Forecast ($bn, AGR %, CAGR %), 2011-2016
Table 4.25 Allergan: Market Forecast ($bn, AGR %, CAGR %), 2017-2022
Table 5.1 Sanofi: Key Facts, 2012
Table 5.2 Sanofi: Leading Biologics, Revenues ($bn), Share of Revenues (%), 2011
Table 5.3 Sanofi: Selected Phase III Pipeline Biologics, 2012
Table 5.4 Sanofi: Selected Phase I and Phase II Pipeline Biologics, 2012
Table 5.5 Sanofi: Market Forecast ($bn, AGR %, CAGR %), 2011-2016
Table 5.6 Sanofi: Market Forecast ($bn, AGR %, CAGR %), 2017-2022
Table 5.7 Pfizer: Key Facts, 2012
Table 5.8 Pfizer: Leading Biologics, Revenues ($bn), Share of Revenues (%), 2011
Table 5.9 Pfizer: Selected Phase III and Phase II Pipeline, 2012
Table 5.10 Pfizer: Selected Early-Stage Pipeline, 2012
Table 5.11 Pfizer: Market Forecast ($bn, AGR %, CAGR %), 2011-2016
Table 5.12 Pfizer: Market Forecast ($bn, AGR %, CAGR %), 2017-2022
Table 5.13 GlaxoSmithKline: Key Facts, 2012
Table 5.14 GlaxoSmithKline: Leading Biologics, Revenues ($bn), Share of Revenues (%), 2011
Table 5.15 GlaxoSmithKline: Selected Late-Stage Pipeline, 2012
Table 5.16 GlaxoSmithKline: Selected Phase I and Phase II Pipeline, 2012
Table 5.17 GlaxoSmithKline: Market Forecast ($bn, AGR %, CAGR %), 2011-2016
Table 5.18 GlaxoSmithKline: Market Forecast ($bn, AGR %, CAGR %), 2017-2022
Table 5.19 Merck: Key Facts, 2012
Table 5.20 Leading Biologics, Revenues ($bn), Share of Revenues (%), 2011
Table 5.21 Merck: Selected Pipeline Biologics, 2012
Table 5.22 Merck: Market Forecast ($bn, AGR %, CAGR %), 2011-2016
Table 5.23 Merck: Market Forecast ($bn, AGR %, CAGR %), 2017-2022
Table 5.24 Novartis: Key Facts, 2012
Table 5.25 Leading Novartis Biologics, Revenues ($bn), Share of Revenues (%), 2011
Table 5.26 Novartis: Selected Pipeline Biologics, 2012
Table 5.27 Novartis: Market Forecast ($bn, AGR %, CAGR %), 2011-2016
Table 5.28 Novartis: Market Forecast ($bn, AGR %, CAGR %), 2017-2022
Table 6.1 Novo Nordisk: Key Facts, 2012
Table 6.2 Novo Nordisk Leading Biologics, Revenues ($bn), Share of Revenues (%), 2011
Table 6.3 Novo Nordisk: Selected Pipeline Biologics, 2012
Table 6.4 Novo Nordisk Biologics, Market Forecast ($bn, AGR %, CAGR %), 2011-2016
Table 6.5 Novo Nordisk Biologics, Market Forecast ($bn, AGR %, CAGR %), 2017-2022
Table 6.6 Merck KGaA: Key Facts, 2012
Table 6.7 Merck KGaA Leading Biologics, Revenues ($bn), Share of Revenues (%), 2011
Table 6.8 Merck KGaA Selected Pipeline, 2012
Table 6.9 Merck KGaA Biologics, Market Forecast ($bn, AGR %, CAGR %), 2011-2016
Table 6.10 Merck KGaA Biologics, Market Forecast ($bn, AGR %, CAGR %), 2017-2022
Table 6.11 Bayer: Key Facts, 2012
Table 6.12 Bayer Leading Biologics, Revenues ($bn), Share of Revenues (%), 2011
Table 6.13 Bayer Selected Pipeline, 2012
Table 6.14 Bayer Biologics, Market Forecast ($bn, AGR %, CAGR %), 2011-2016
Table 6.15 Bayer Biologics, Market Forecast ($bn, AGR %, CAGR %), 2017-2022
Table 6.16 AstraZeneca: Key Facts, 2012
Table 6.17 AstraZeneca: Leading Biologics, Revenues ($bn), Share of Total Revenues (%), 2011
Table 6.18 AstraZeneca: Selected Biologics Pipeline, 2012
Table 6.19 AstraZeneca Biologics, Market Forecast ($bn, AGR %, CAGR %), 2011-2016
Table 6.20 AstraZeneca Biologics, Market Forecast ($bn, AGR %, CAGR %), 2017-2022
Table 7.1 Johnson & Johnson: Key Facts, 2012
Table 7.2 Johnson & Johnson: Leading Biologics, Revenues ($bn), Share of Total Revenues (%), 2011
Table 7.3 Johnson & Johnson Selected Pipeline, 2011
Table 7.4 Johnson & Johnson Biologics, Market Forecast ($bn, AGR %, CAGR %), 2011-2016
Table 7.5 Johnson & Johnson Biologics, Market Forecast ($bn, AGR %, CAGR %), 2017-2022
Table 7.6 Abbott Laboratories: Key Facts, 2012
Table 7.7 Abbott: Leading Biologics, Revenues ($bn), Share of Total Revenues (%), 2011
Table 7.8 Abbott: Selected Pipeline, 2012
Table 7.9 Abbott Laboratories Biologics, Market Forecast ($bn, AGR %, CAGR %), 2011-2016
Table 7.10 Abbott Laboratories Biologics, Market Forecast ($bn, AGR %, CAGR %), 2017-2022
Table 7.11 Baxter: Key Facts, 2012
Table 7.12 Baxter: Leading Biologics, Revenues ($bn), Share of Total Revenues (%), 2011
Table 7.13 Baxter: Selected Pipeline, 2012
Table 7.14 Baxter Biologics, Market Forecast ($bn, AGR %, CAGR %), 2011-2016
Table 7.15 Baxter Biologics, Market Forecast ($bn, AGR %, CAGR %), 2017-2022
Table 7.16 Eli Lilly: Key Facts, 2012
Table 7.17 Eli Lilly: Leading Biologics, Revenues ($bn), Share of Total Revenues (%), 2011
Table 7.18 Eli Lilly: Selected Biologics Pipeline, 2012
Table 7.19 Eli Lilly Biologics, Market Forecast ($bn, AGR %, CAGR %), 2011-2016
Table 7.20 Eli Lilly Biologics, Market Forecast ($bn, AGR %, CAGR %), 2017-2022
Table 7.21 Bristol-Myers Squibb: Key Facts, 2012
Table 7.22 Bristol-Myers Squibb: Leading Biologics, Revenues ($bn), Share of Total Revenues (%), 2011
Table 7.23 Bristol-Myers Squibb: Selected Biologics Pipeline, 2012
Table 7.24 Bristol-Myers Squibb Biologics, Market Forecast ($bn, AGR %, CAGR %), 2011-2016
Table 7.25 Bristol-Myers Squibb Biologics, Market Forecast ($bn, AGR %, CAGR %), 2017-2022
Table 1.1 Currency Exchange Rates, 2011
Table 2.2 Biological Drugs Market by Class, Revenues ($bn), Market Share (%), 2011
Table 2.3 Therapeutic Proteins: Role in the Biological Drugs Market, 2011
Table 2.4 MAbs: Role in the Biological Drugs Market, 2011
Table 2.5 Vaccines: Role in the Biological Drugs Market, 2011
Table 2.6 Fusion Proteins: Role in the Biological Drugs Market, 2011
Table 2.7 Other Biologics: Role in the Biological Drugs Market, 2011
Table 2.8 Biological Drugs Market by Class: Revenues ($bn), Market Share (%), CAGR (%), 2011, 2016, 2022
Table 2.9 Top 20 Biological Manufacturers: Revenue ($bn), Market Share (%), 2011
Table 3.1 Roche: Key Facts, 2012
Table 3.2 Roche: Leading Biologics, Revenues ($bn), Share of Biologics Revenue (%), 2011
Table 3.3 Roche: Selected Pipeline Biologics, Phase II and III, 2012
Table 3.4 Roche: Selected Pipeline Biologics, Phase I, 2012
Table 3.5 Roche Biologics, Market Forecast ($bn, AGR %, CAGR %), 2011-2016
Table 3.6 Roche Biologics, Market Forecast ($bn, AGR %, CAGR %), 2017-2022
Table 4.1 Amgen: Key Facts, 2012
Table 4.2 Amgen: Key M&A Deals, 2012
Table 4.3 Amgen: Lead Biologics Revenues ($bn), Share of Biologics Revenue (%), 2011
Table 4.4 Amgen: Selected Pipeline Biologics, 2012
Table 4.5 Amgen: Market Forecast ($bn, AGR %, CAGR %), 2011-2016
Table 4.6 Amgen: Market Forecast ($bn, AGR %, CAGR %), 2017-2022
Table 4.7 Biogen Idec: Key Facts, 2012
Table 4.8 Biogen Idec: Ongoing Collaborations, 2012
Table 4.9 Biogen Idec: Lead Biologics Revenues ($bn), Share of Biologics Revenue (%), 2011
Table 4.10 Biogen Idec: Selected Pipeline Biologics, 2012
Table 4.11 Biogen Idec: Market Forecast ($bn, AGR %, CAGR %), 2011-2016
Table 4.12 Biogen Idec: Market Forecast ($bn, AGR %, CAGR %), 2017-2022
Table 4.13 CSL Behring: Key Facts, 2012
Table 4.14 CSL: Shares of Company's Biologics Revenue (%), 2011
Table 4.15 CSL: Selected Pipeline Biologics, 2012
Table 4.16 CSL: Market Forecast ($bn, AGR %, CAGR %), 2011-2016
Table 4.17 CSL: Market Forecast ($bn, AGR %, CAGR %), 2017-2022
Table 4.18 Grifols: Key Facts, 2012
Table 4.19 Grifols: Selected Biologics, Revenues ($bn), 2010
Table 4.20 Grifols: Market Forecast ($bn, AGR %, CAGR %), 2011-2016
Table 4.21 Grifols: Market Forecast ($bn, AGR %, CAGR %), 2017-2022
Table 4.22 Allergan: Key Facts, 2012
Table 4.23 FDA-Approved On-Label Uses of Botox with Approval Date, 2012
Table 4.24 Allergan: Market Forecast ($bn, AGR %, CAGR %), 2011-2016
Table 4.25 Allergan: Market Forecast ($bn, AGR %, CAGR %), 2017-2022
Table 5.1 Sanofi: Key Facts, 2012
Table 5.2 Sanofi: Leading Biologics, Revenues ($bn), Share of Revenues (%), 2011
Table 5.3 Sanofi: Selected Phase III Pipeline Biologics, 2012
Table 5.4 Sanofi: Selected Phase I and Phase II Pipeline Biologics, 2012
Table 5.5 Sanofi: Market Forecast ($bn, AGR %, CAGR %), 2011-2016
Table 5.6 Sanofi: Market Forecast ($bn, AGR %, CAGR %), 2017-2022
Table 5.7 Pfizer: Key Facts, 2012
Table 5.8 Pfizer: Leading Biologics, Revenues ($bn), Share of Revenues (%), 2011
Table 5.9 Pfizer: Selected Phase III and Phase II Pipeline, 2012
Table 5.10 Pfizer: Selected Early-Stage Pipeline, 2012
Table 5.11 Pfizer: Market Forecast ($bn, AGR %, CAGR %), 2011-2016
Table 5.12 Pfizer: Market Forecast ($bn, AGR %, CAGR %), 2017-2022
Table 5.13 GlaxoSmithKline: Key Facts, 2012
Table 5.14 GlaxoSmithKline: Leading Biologics, Revenues ($bn), Share of Revenues (%), 2011
Table 5.15 GlaxoSmithKline: Selected Late-Stage Pipeline, 2012
Table 5.16 GlaxoSmithKline: Selected Phase I and Phase II Pipeline, 2012
Table 5.17 GlaxoSmithKline: Market Forecast ($bn, AGR %, CAGR %), 2011-2016
Table 5.18 GlaxoSmithKline: Market Forecast ($bn, AGR %, CAGR %), 2017-2022
Table 5.19 Merck: Key Facts, 2012
Table 5.20 Leading Biologics, Revenues ($bn), Share of Revenues (%), 2011
Table 5.21 Merck: Selected Pipeline Biologics, 2012
Table 5.22 Merck: Market Forecast ($bn, AGR %, CAGR %), 2011-2016
Table 5.23 Merck: Market Forecast ($bn, AGR %, CAGR %), 2017-2022
Table 5.24 Novartis: Key Facts, 2012
Table 5.25 Leading Novartis Biologics, Revenues ($bn), Share of Revenues (%), 2011
Table 5.26 Novartis: Selected Pipeline Biologics, 2012
Table 5.27 Novartis: Market Forecast ($bn, AGR %, CAGR %), 2011-2016
Table 5.28 Novartis: Market Forecast ($bn, AGR %, CAGR %), 2017-2022
Table 6.1 Novo Nordisk: Key Facts, 2012
Table 6.2 Novo Nordisk Leading Biologics, Revenues ($bn), Share of Revenues (%), 2011
Table 6.3 Novo Nordisk: Selected Pipeline Biologics, 2012
Table 6.4 Novo Nordisk Biologics, Market Forecast ($bn, AGR %, CAGR %), 2011-2016
Table 6.5 Novo Nordisk Biologics, Market Forecast ($bn, AGR %, CAGR %), 2017-2022
Table 6.6 Merck KGaA: Key Facts, 2012
Table 6.7 Merck KGaA Leading Biologics, Revenues ($bn), Share of Revenues (%), 2011
Table 6.8 Merck KGaA Selected Pipeline, 2012
Table 6.9 Merck KGaA Biologics, Market Forecast ($bn, AGR %, CAGR %), 2011-2016
Table 6.10 Merck KGaA Biologics, Market Forecast ($bn, AGR %, CAGR %), 2017-2022
Table 6.11 Bayer: Key Facts, 2012
Table 6.12 Bayer Leading Biologics, Revenues ($bn), Share of Revenues (%), 2011
Table 6.13 Bayer Selected Pipeline, 2012
Table 6.14 Bayer Biologics, Market Forecast ($bn, AGR %, CAGR %), 2011-2016
Table 6.15 Bayer Biologics, Market Forecast ($bn, AGR %, CAGR %), 2017-2022
Table 6.16 AstraZeneca: Key Facts, 2012
Table 6.17 AstraZeneca: Leading Biologics, Revenues ($bn), Share of Total Revenues (%), 2011
Table 6.18 AstraZeneca: Selected Biologics Pipeline, 2012
Table 6.19 AstraZeneca Biologics, Market Forecast ($bn, AGR %, CAGR %), 2011-2016
Table 6.20 AstraZeneca Biologics, Market Forecast ($bn, AGR %, CAGR %), 2017-2022
Table 7.1 Johnson & Johnson: Key Facts, 2012
Table 7.2 Johnson & Johnson: Leading Biologics, Revenues ($bn), Share of Total Revenues (%), 2011
Table 7.3 Johnson & Johnson Selected Pipeline, 2011
Table 7.4 Johnson & Johnson Biologics, Market Forecast ($bn, AGR %, CAGR %), 2011-2016
Table 7.5 Johnson & Johnson Biologics, Market Forecast ($bn, AGR %, CAGR %), 2017-2022
Table 7.6 Abbott Laboratories: Key Facts, 2012
Table 7.7 Abbott: Leading Biologics, Revenues ($bn), Share of Total Revenues (%), 2011
Table 7.8 Abbott: Selected Pipeline, 2012
Table 7.9 Abbott Laboratories Biologics, Market Forecast ($bn, AGR %, CAGR %), 2011-2016
Table 7.10 Abbott Laboratories Biologics, Market Forecast ($bn, AGR %, CAGR %), 2017-2022
Table 7.11 Baxter: Key Facts, 2012
Table 7.12 Baxter: Leading Biologics, Revenues ($bn), Share of Total Revenues (%), 2011
Table 7.13 Baxter: Selected Pipeline, 2012
Table 7.14 Baxter Biologics, Market Forecast ($bn, AGR %, CAGR %), 2011-2016
Table 7.15 Baxter Biologics, Market Forecast ($bn, AGR %, CAGR %), 2017-2022
Table 7.16 Eli Lilly: Key Facts, 2012
Table 7.17 Eli Lilly: Leading Biologics, Revenues ($bn), Share of Total Revenues (%), 2011
Table 7.18 Eli Lilly: Selected Biologics Pipeline, 2012
Table 7.19 Eli Lilly Biologics, Market Forecast ($bn, AGR %, CAGR %), 2011-2016
Table 7.20 Eli Lilly Biologics, Market Forecast ($bn, AGR %, CAGR %), 2017-2022
Table 7.21 Bristol-Myers Squibb: Key Facts, 2012
Table 7.22 Bristol-Myers Squibb: Leading Biologics, Revenues ($bn), Share of Total Revenues (%), 2011
Table 7.23 Bristol-Myers Squibb: Selected Biologics Pipeline, 2012
Table 7.24 Bristol-Myers Squibb Biologics, Market Forecast ($bn, AGR %, CAGR %), 2011-2016
Table 7.25 Bristol-Myers Squibb Biologics, Market Forecast ($bn, AGR %, CAGR %), 2017-2022
LIST OF FIGURES
Figure 2.1 Biological Drugs Market by Class, Market Share (%), 2011
Figure 2.2 Biological Drugs Market by Class: Revenues ($bn), 2011, 2016, 2022
Figure 2.3 Biological Drugs Market: Drivers and Restraints, 2012-2022
Figure 2.4 Top 20 Biological Manufacturers: Market Share (%), 2011
Figure 3.1 Regional Distribution of Roche Sales (%), 2011
Figure 3.2 Roche: Leading Biologics, Share of Total Revenues (%), 2011
Figure 3.3 Drivers and Restraints for Roche Biologics, 2012
Figure 3.4 Roche: Market Forecast ($bn), 2011-2022
Figure 4.1 Amgen: Lead Biologics Share of Overall Revenues (%), 2011
Figure 4.2 Drivers and Restraints for Amgen Biologics, 2012
Figure 4.3 Amgen: Market Forecast ($bn), 2011-2022
Figure 4.4 Biogen Idec: Lead Biologics Share of Overall Revenues (%), 2011
Figure 4.5 Biogen Idec: Drivers and Restraints, 2012
Figure 4.6 Biogen Idec: Market Forecast ($bn), 2011-2022
Figure 4.7 CSL Behring: Regional Breakdown of Revenues (%), 2011
Figure 4.8 CSL Behring: Lead Biologics Share of Revenues (%), 2011.
Figure 4.9 Drivers and Restraints for CSL Biologics, 2012
Figure 4.10 CSL Behring: Market Forecast ($bn), 2011-2022
Figure 4.11 Grifols: Breakdown of Revenues by Business Segment (%), 2011
Figure 4.12 Grifols: Regional Distribution of Revenues (%), 2009-2011
Figure 4.13 Grifols: Selected Biologics ($bn), 2010
Figure 4.14 Drivers and Restraints for Grifols Biologics, 2012
Figure 4.15 Grifols: Market Forecast ($bn), 2011-2022
Figure 4.16 Allergan: Breakdown of Pharmaceutical Revenues (%), 2011
Figure 4.17 Allergan: Geographical Breakdown of Revenues (%), 2011
Figure 4.18 Drivers and Restraints for Allergan Biologics, 2012
Figure 4.19 Allergan: Market Forecast ($bn), 2011-2022
Figure 5.1 Sanofi: Revenue Breakdown by Business Segment (%), 2011
Figure 5.2 Sanofi: Leading Biologics, Share of Revenues (%), 2011
Figure 5.3 Drivers and Restraints for Sanofi Biologics, 2012
Figure 5.4 Sanofi: Market Forecast ($bn), 2011-2022
Figure 5.5 Pfizer: Leading Biologics, Share of Revenues (%), 2011
Figure 5.6 Drivers and Restraints for Pfizer Biologics, 2012
Figure 5.7 Pfizer: Market Forecast ($bn), 2011-2022
Figure 5.8 GlaxoSmithKline: Business Breakdown by Segment (%), 2011
Figure 5.9 Drivers and Restraints for GlaxoSmithKline Biologics, 2012
Figure 5.10 GlaxoSmithKline: Market Forecast ($bn), 2011-2022
Figure 5.11 Leading Biologics, Share of Revenues (%), 2011
Figure 5.12 Drivers and Restraints for Merck Biologics, 2012
Figure 5.13 Merck: Market Forecast ($bn), 2011-2022
Figure 5.14 Leading Novartis Biologics, Share of Revenues (%), 2011
Figure 5.15 Drivers and Restraints for Novartis Biologics, 2012
Figure 5.16 Novartis: Market Forecast ($bn), 2011-2022
Figure 6.1 Novo Nordisk: Revenue Breakdown (%) by Business Segment, 2012
Figure 6.2 Novo Nordisk Leading Biologics, Share of Revenues (%), 2011
Figure 6.3 Drivers and Restraints for Novo Nordisk Biologics, 2012
Figure 6.4 Novo Nordisk Market Forecast ($bn), 2011-2022
Figure 6.5 Merck KGaA Leading Biologics, Share of Revenues (%), 2011
Figure 6.6 Drivers and Restraints for Merck KGaA, 2012
Figure 6.7 Merck KGaA Biologics, Market Forecast ($bn), 2011-2022
Figure 6.8 Bayer: Distribution of Revenues by Business (%), 2011
Figure 6.9 Bayer: Distribution of Revenues by Region (%), 2011
Figure 6.10 Bayer Leading Biologics, Share of Revenues (%), 2011
Figure 6.11 Drivers and Restraints for Bayer Biologics, 2012
Figure 6.12 Bayer Biologics, Market Forecast ($bn), 2011-2022
Figure 6.13 AstraZeneca: Regional Distribution of Revenues (%), 2011
Figure 6.14 AstraZeneca: Leading Biologics, Share of Total Revenues (%), 2011
Figure 6.15 Drivers and Restraints for AstraZeneca Biologics, 2012
Figure 6.16 AstraZeneca Biologics, Market Forecast ($bn), 2011-2022
Figure 7.1 Johnson & Johnson: Revenues Breakdown by Business Segment (%), 2012
Figure 7.2 Johnson & Johnson: Leading Biologics, Share of Total Revenues (%), 2011
Figure 7.3 Drivers and Restraints for Johnson & Johnson Biologics, 2012
Figure 7.4 Johnson & Johnson Biologics, Market Forecast ($bn), 2011-2022
Figure 7.5 Abbott Laboratories: Revenue Breakdown by Business Segment (%), 2012
Figure 7.6 Abbott: Leading Biologics, Share of Total Revenues (%), 2011
Figure 7.7 Drivers and Restraints for Abbott, 2012
Figure 7.8 Abbott Laboratories Biologics, Market Forecast ($bn), 2011-2022
Figure 7.9 Baxter: Breakdown of Revenues by Business (%), 2011
Figure 7.10 Baxter: Breakdown of Revenues by Region (%), 2011
Figure 7.11 Baxter: Share of Total Revenues (%), 2011
Figure 7.12 Drivers and Restraints for Baxter Biologics, 2012
Figure 7.13 Baxter Biologics, Market Forecast ($bn), 2011-2022
Figure 7.14 Eli Lilly: Breakdown of Pharmaceutical Sales by Therapeutic Area (%), 2011
Figure 7.15 Eli Lilly: Leading Biologics, Share of Total Revenues (%), 2011
Figure 7.16 Drivers and Restraints for Eli Lilly Biologics, 2012
Figure 7.17 Eli Lilly Biologics, Market Forecast ($bn), 2011-2022
Figure 7.18 Bristol-Myers Squibb: Regional Distribution of Revenues (%), 2011
Figure 7.19 Bristol-Myers Squibb: Leading Biologics, Share of Total Revenues (%), 2011
Figure 7.20 Drivers and Restraints for Bristol-Myers Squibb Biologics, 2012
Figure 7.21 Bristol-Myers Squibb Biologics, Market Forecast ($bn), 2011-2022
COMPANIES LISTED
Abbott Laboratories
Abgenix
Ablynx
AC Immune
Acadia Pharmaceuticals
Acorda Therapeutics
Alantos Pharmaceuticals
ALK Abello
Allergan
Alnara Pharmaceuticals
Amgen
AstraZeneca
Avidia
Baxter International
Bayer HealthCare
Becton Dickinson
Biogen Idec
Bioheart
Biomira
BioVex
Boehringer Ingelheim
Bristol-Myers Squibb (BMS)
Cambridge Antibody Technologies
Centocor Ortho Biotech
Chinese Academy of Medical Sciences
Chinese Academy of Sciences
Chiron
Cilag Chemie
Coley Pharmaceuticals
Corixa
Cougar Biotechnology
CovX
Crucell Biotechnology
CSL Behring
CSL Biotherapies
CT Arztneimittel
Cytori
Dompé
Duke University
Dyax
Dynavax
Eisai
Elan
Eli Lilly
EMD Serono
Encysive Pharmaceuticals
ExonHit Therapeutics
Facet Biotech
Fresenius
F-Star
Galena Biopharma
Genentech
Genesis Pharma
Genetics Institute
Genmab
Genzyme
GlaxoSmithKline
GlycoFi
Grifols
GTC Biotherapeutics
HD Biosciences
Hexal
Hoechst Marion Roussel
Hospira
HudsonAlpha Institute for Biotechnology
Human Genome Sciences
Hutchison MediPharma
ID Biomedical
Ilypsa
ImClone
Immunex Corporation
ImmunoGen
Inspire Pharmaceuticals
Institute for Genomic Research
International Vaccine Institute
Ipsen
Janssen Pharmaceutica
Jiangsu Walvax Biotech Company
Johns Hopkins University
Johnson & Johnson
KAI Pharmaceuticals
Kinetix Pharmaceuticals
King
Knopp Neurosciences
Kuros
Kyorin Pharmaceutical
Kyowa Hakko Kirin
Lipoxen
Ludwig Institute for Cancer Research
McNeil Laboratories
Medarex
MedImmune
Medixion
Megapharm
Merck & Co.
Merck BioVentures
Merck KGaA
Merck-Banyu
Merz Pharma
Micromet
Millipore
Mitsubishi Tanabe Pharma
Molecular Partners
MorphoSys
Mustafa Nevzat Pharmaceuticals
National Center for Drug Screening (China)
Nestlé
Neurimmune SubOne
Novartis
Novo Nordisk
Oncothyreon
Ortho Pharmaceutical
Oxford University
Pasteur Merieux Serums & Vaccins
PDL BioPharma
Peptech
Pfizer
Pharmacia
Philogen
Pieris
Piramal
Portola Pharmaceuticals
PowderMed
Protein Design
Regeneron
Roche
Sabin Vaccine Institute
Samsung Biologics
Sandoz
Sanofi
Sanofi Pasteur MSD
Sanwa Kagaku Kenkyusho
Schering-Plough
Senju Pharmaceutical
Serenex
Shanghai ChemExplorer
Shanghai Institute of Biological Sciences
Shanghai Institute of Materia Medica
Shantha Biotechnics
Sirna Therapeutics
Solvay Pharmaceuticals
Swedish Orphan Biovitrum
Synergen
Synovis Life Technologies
Syntonix
Takeda
Talecris
Teva Pharmaceutical Industries
Tianjin Medical University Cancer Hospital
Transkaryotic Therapies
Trellis Bioscience
Trubion
Tularik
University of Queensland
Upjohn
Vaxdesign
Vernalis
VIVALis
Walter Reed Army Institute
Warner-Lambert
World Health Organization (WHO)
WuXi AppTec
Wyeth Pharmaceuticals
Zhejiang Taiyuan
Zydus Cadila
ZymoGenetics
Figure 2.1 Biological Drugs Market by Class, Market Share (%), 2011
Figure 2.2 Biological Drugs Market by Class: Revenues ($bn), 2011, 2016, 2022
Figure 2.3 Biological Drugs Market: Drivers and Restraints, 2012-2022
Figure 2.4 Top 20 Biological Manufacturers: Market Share (%), 2011
Figure 3.1 Regional Distribution of Roche Sales (%), 2011
Figure 3.2 Roche: Leading Biologics, Share of Total Revenues (%), 2011
Figure 3.3 Drivers and Restraints for Roche Biologics, 2012
Figure 3.4 Roche: Market Forecast ($bn), 2011-2022
Figure 4.1 Amgen: Lead Biologics Share of Overall Revenues (%), 2011
Figure 4.2 Drivers and Restraints for Amgen Biologics, 2012
Figure 4.3 Amgen: Market Forecast ($bn), 2011-2022
Figure 4.4 Biogen Idec: Lead Biologics Share of Overall Revenues (%), 2011
Figure 4.5 Biogen Idec: Drivers and Restraints, 2012
Figure 4.6 Biogen Idec: Market Forecast ($bn), 2011-2022
Figure 4.7 CSL Behring: Regional Breakdown of Revenues (%), 2011
Figure 4.8 CSL Behring: Lead Biologics Share of Revenues (%), 2011.
Figure 4.9 Drivers and Restraints for CSL Biologics, 2012
Figure 4.10 CSL Behring: Market Forecast ($bn), 2011-2022
Figure 4.11 Grifols: Breakdown of Revenues by Business Segment (%), 2011
Figure 4.12 Grifols: Regional Distribution of Revenues (%), 2009-2011
Figure 4.13 Grifols: Selected Biologics ($bn), 2010
Figure 4.14 Drivers and Restraints for Grifols Biologics, 2012
Figure 4.15 Grifols: Market Forecast ($bn), 2011-2022
Figure 4.16 Allergan: Breakdown of Pharmaceutical Revenues (%), 2011
Figure 4.17 Allergan: Geographical Breakdown of Revenues (%), 2011
Figure 4.18 Drivers and Restraints for Allergan Biologics, 2012
Figure 4.19 Allergan: Market Forecast ($bn), 2011-2022
Figure 5.1 Sanofi: Revenue Breakdown by Business Segment (%), 2011
Figure 5.2 Sanofi: Leading Biologics, Share of Revenues (%), 2011
Figure 5.3 Drivers and Restraints for Sanofi Biologics, 2012
Figure 5.4 Sanofi: Market Forecast ($bn), 2011-2022
Figure 5.5 Pfizer: Leading Biologics, Share of Revenues (%), 2011
Figure 5.6 Drivers and Restraints for Pfizer Biologics, 2012
Figure 5.7 Pfizer: Market Forecast ($bn), 2011-2022
Figure 5.8 GlaxoSmithKline: Business Breakdown by Segment (%), 2011
Figure 5.9 Drivers and Restraints for GlaxoSmithKline Biologics, 2012
Figure 5.10 GlaxoSmithKline: Market Forecast ($bn), 2011-2022
Figure 5.11 Leading Biologics, Share of Revenues (%), 2011
Figure 5.12 Drivers and Restraints for Merck Biologics, 2012
Figure 5.13 Merck: Market Forecast ($bn), 2011-2022
Figure 5.14 Leading Novartis Biologics, Share of Revenues (%), 2011
Figure 5.15 Drivers and Restraints for Novartis Biologics, 2012
Figure 5.16 Novartis: Market Forecast ($bn), 2011-2022
Figure 6.1 Novo Nordisk: Revenue Breakdown (%) by Business Segment, 2012
Figure 6.2 Novo Nordisk Leading Biologics, Share of Revenues (%), 2011
Figure 6.3 Drivers and Restraints for Novo Nordisk Biologics, 2012
Figure 6.4 Novo Nordisk Market Forecast ($bn), 2011-2022
Figure 6.5 Merck KGaA Leading Biologics, Share of Revenues (%), 2011
Figure 6.6 Drivers and Restraints for Merck KGaA, 2012
Figure 6.7 Merck KGaA Biologics, Market Forecast ($bn), 2011-2022
Figure 6.8 Bayer: Distribution of Revenues by Business (%), 2011
Figure 6.9 Bayer: Distribution of Revenues by Region (%), 2011
Figure 6.10 Bayer Leading Biologics, Share of Revenues (%), 2011
Figure 6.11 Drivers and Restraints for Bayer Biologics, 2012
Figure 6.12 Bayer Biologics, Market Forecast ($bn), 2011-2022
Figure 6.13 AstraZeneca: Regional Distribution of Revenues (%), 2011
Figure 6.14 AstraZeneca: Leading Biologics, Share of Total Revenues (%), 2011
Figure 6.15 Drivers and Restraints for AstraZeneca Biologics, 2012
Figure 6.16 AstraZeneca Biologics, Market Forecast ($bn), 2011-2022
Figure 7.1 Johnson & Johnson: Revenues Breakdown by Business Segment (%), 2012
Figure 7.2 Johnson & Johnson: Leading Biologics, Share of Total Revenues (%), 2011
Figure 7.3 Drivers and Restraints for Johnson & Johnson Biologics, 2012
Figure 7.4 Johnson & Johnson Biologics, Market Forecast ($bn), 2011-2022
Figure 7.5 Abbott Laboratories: Revenue Breakdown by Business Segment (%), 2012
Figure 7.6 Abbott: Leading Biologics, Share of Total Revenues (%), 2011
Figure 7.7 Drivers and Restraints for Abbott, 2012
Figure 7.8 Abbott Laboratories Biologics, Market Forecast ($bn), 2011-2022
Figure 7.9 Baxter: Breakdown of Revenues by Business (%), 2011
Figure 7.10 Baxter: Breakdown of Revenues by Region (%), 2011
Figure 7.11 Baxter: Share of Total Revenues (%), 2011
Figure 7.12 Drivers and Restraints for Baxter Biologics, 2012
Figure 7.13 Baxter Biologics, Market Forecast ($bn), 2011-2022
Figure 7.14 Eli Lilly: Breakdown of Pharmaceutical Sales by Therapeutic Area (%), 2011
Figure 7.15 Eli Lilly: Leading Biologics, Share of Total Revenues (%), 2011
Figure 7.16 Drivers and Restraints for Eli Lilly Biologics, 2012
Figure 7.17 Eli Lilly Biologics, Market Forecast ($bn), 2011-2022
Figure 7.18 Bristol-Myers Squibb: Regional Distribution of Revenues (%), 2011
Figure 7.19 Bristol-Myers Squibb: Leading Biologics, Share of Total Revenues (%), 2011
Figure 7.20 Drivers and Restraints for Bristol-Myers Squibb Biologics, 2012
Figure 7.21 Bristol-Myers Squibb Biologics, Market Forecast ($bn), 2011-2022
COMPANIES LISTED
Abbott Laboratories
Abgenix
Ablynx
AC Immune
Acadia Pharmaceuticals
Acorda Therapeutics
Alantos Pharmaceuticals
ALK Abello
Allergan
Alnara Pharmaceuticals
Amgen
AstraZeneca
Avidia
Baxter International
Bayer HealthCare
Becton Dickinson
Biogen Idec
Bioheart
Biomira
BioVex
Boehringer Ingelheim
Bristol-Myers Squibb (BMS)
Cambridge Antibody Technologies
Centocor Ortho Biotech
Chinese Academy of Medical Sciences
Chinese Academy of Sciences
Chiron
Cilag Chemie
Coley Pharmaceuticals
Corixa
Cougar Biotechnology
CovX
Crucell Biotechnology
CSL Behring
CSL Biotherapies
CT Arztneimittel
Cytori
Dompé
Duke University
Dyax
Dynavax
Eisai
Elan
Eli Lilly
EMD Serono
Encysive Pharmaceuticals
ExonHit Therapeutics
Facet Biotech
Fresenius
F-Star
Galena Biopharma
Genentech
Genesis Pharma
Genetics Institute
Genmab
Genzyme
GlaxoSmithKline
GlycoFi
Grifols
GTC Biotherapeutics
HD Biosciences
Hexal
Hoechst Marion Roussel
Hospira
HudsonAlpha Institute for Biotechnology
Human Genome Sciences
Hutchison MediPharma
ID Biomedical
Ilypsa
ImClone
Immunex Corporation
ImmunoGen
Inspire Pharmaceuticals
Institute for Genomic Research
International Vaccine Institute
Ipsen
Janssen Pharmaceutica
Jiangsu Walvax Biotech Company
Johns Hopkins University
Johnson & Johnson
KAI Pharmaceuticals
Kinetix Pharmaceuticals
King
Knopp Neurosciences
Kuros
Kyorin Pharmaceutical
Kyowa Hakko Kirin
Lipoxen
Ludwig Institute for Cancer Research
McNeil Laboratories
Medarex
MedImmune
Medixion
Megapharm
Merck & Co.
Merck BioVentures
Merck KGaA
Merck-Banyu
Merz Pharma
Micromet
Millipore
Mitsubishi Tanabe Pharma
Molecular Partners
MorphoSys
Mustafa Nevzat Pharmaceuticals
National Center for Drug Screening (China)
Nestlé
Neurimmune SubOne
Novartis
Novo Nordisk
Oncothyreon
Ortho Pharmaceutical
Oxford University
Pasteur Merieux Serums & Vaccins
PDL BioPharma
Peptech
Pfizer
Pharmacia
Philogen
Pieris
Piramal
Portola Pharmaceuticals
PowderMed
Protein Design
Regeneron
Roche
Sabin Vaccine Institute
Samsung Biologics
Sandoz
Sanofi
Sanofi Pasteur MSD
Sanwa Kagaku Kenkyusho
Schering-Plough
Senju Pharmaceutical
Serenex
Shanghai ChemExplorer
Shanghai Institute of Biological Sciences
Shanghai Institute of Materia Medica
Shantha Biotechnics
Sirna Therapeutics
Solvay Pharmaceuticals
Swedish Orphan Biovitrum
Synergen
Synovis Life Technologies
Syntonix
Takeda
Talecris
Teva Pharmaceutical Industries
Tianjin Medical University Cancer Hospital
Transkaryotic Therapies
Trellis Bioscience
Trubion
Tularik
University of Queensland
Upjohn
Vaxdesign
Vernalis
VIVALis
Walter Reed Army Institute
Warner-Lambert
World Health Organization (WHO)
WuXi AppTec
Wyeth Pharmaceuticals
Zhejiang Taiyuan
Zydus Cadila
ZymoGenetics
